OCM
ALLO icon

Osterweis Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Osterweis Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,486
Closed -$235K – 115
2020
Q2 		$235K Buy
+5,486
New +$198K 0.02% 107
2019
Q3 		– Sell
-11,283
Closed -$303K – 109
2019
Q2 		$303K Buy
+11,283
New +$314K 0.02% 97

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Osterweis Capital Management's ALLO Position: Q3 2020 in Review

Osterweis Capital Management sold out of Allogene Therapeutics (ALLO) in Q3 2020, closing a stake of 5,486 shares — an estimated $235K sold.

Osterweis Capital Management first reported a position in ALLO in Q2 2019 and held it in 2 quarters. The position peaked at $303K in Q2 2019. 162 funds tracked by Wall St. Rank hold ALLO as of Q3 2020.

  • Osterweis Capital Management reported no remaining Allogene Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Osterweis Capital Management sold 5,486 Allogene Therapeutics shares in Q3 2020, an estimated $235K.
  • Osterweis Capital Management first reported a position in Allogene Therapeutics in Q2 2019 and held it in 2 quarters.
  • Osterweis Capital Management's Allogene Therapeutics position peaked at $303K in Q2 2019.
  • 162 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2020.

Based on Osterweis Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.